MediWound Ltd. MDWD

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The f

Moby summary of MediWound Ltd.'s Q2 2026 earnings call

MediWound Ltd (MDWD) reaffirms 2026 guidance with record NexoBrid quarterly sales, advances EscharEx Phase 3 trial, and expands market opportunity to $1.05 billion in peak annual sales.

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics fo

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. On the same day, MediWound’s management will host a conference call and live webc

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Moby summary of MediWound Ltd.'s Q1 2026 earnings call

MediWound Ltd (MDWD) advances its ESCAREX program and secures a major BARDA contract, despite facing revenue declines and increased R&D expenses.